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Abstract
Introduction High mortality rate, absence of reliable
methods for early diagnosis and poor prognosis of
advanced ovarian cancer prompted to investigate the role
of prophylactic oophorectomy in BRCA1 mutation carriers
as well as evaluate the expression of BRCA1, p53, Nm23,
and KAI1 proteins in ovarian tissue from these patients.
Materials and methods Ovaries from BRCA1 mutation
carriers underwent prophylactic adnexectomy and control
group of patients were operated from other than cancer
reasons. The expression of selected proteins was studied
using immunohistochemical staining. The intensity of
immunostaining and the number of tumor cells showing the
reaction for selected proteins were analyzed.
Results We have analyzed ovarian tissues from 18
BRCA1 mutation carriers and 11 women included in
control group. Positive expression of BRCA1 protein was
presented in 83.3 % cases in BRCA1 mutation carriers and
in 72.7 % in the control group (p [ 0.05). Positive
expression of p53 protein was observed, respectively, in
27.8 vs. 36.4 % (p [ 0.05), Nm23 protein 77.7 vs. 90.9 %
(p [ 0.05), and KAI1 in 72.2 vs. 72.7 % (p [ 0.05). Mean
percent of tumor cells that showed the reaction for selected
proteins as well as the intensity of immunostaining for all
analyzed proteins seems to be lower in BRCA1 mutation
carriers.
Conclusions However, any significant differences
between study group and control group have not been
found; there were similar trends showing reduced expres-
sion of studied proteins in BRCA1 mutation carriers.
Keywords BRCA1  Prophylactic adnexectomy
Introduction
Epithelial ovarian cancer is often referred as the ‘‘silent
killer’’ according to its asymptomatic clinical pattern,
mostly diagnosed in its advanced stages [1]. Approxi-
mately 10 % of ovarian cancer cases are attributed to the
inheritance of a BRCA1 or 2 mutation [2]. The lifetime risk
of ovarian cancer in patients with a BRCA1 mutation is
between 40 and 60 % [1, 3] compared with the general
population risk of 1.8 % [4]. Due to high mortality rate,
absence of reliable methods for early diagnosis and bad
prognosis of advanced stages of ovarian cancer the role of
prophylactic adnexectomy remain the therapy of choice [2,
4]. Especially, assuming significant lifetime risk reduction
for developing ovarian cancer and a low probability of
peritoneal dissemination according to three cohort studies
in patients undergoing bilateral adnexectomy [2].
BRCA1 was identified and cloned in 1994 [1]. This gene
is localized on chromosome 17 (17q21) and codes large
proteins that consist of 1,863 amino acids. BRCA1 protein
has a large number of functions, including regulation of
transcription, embryological development, immune modu-
lation, cell cycle control, and DNA repair [5, 6]. The loss of
the last function leads to accumulation of unrepaired
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somatic mutations what may result in development of
ovarian cancer [5].
The p53 protein has an important biologic function
because it interferes in the response to DNA damage. The
protein accumulates in the cell nucleus and is activated as a
transcription factor in response to DNA damage, hypoxia,
and other genotoxic stresses. It can block the cell cycle in
G1, allowing the cell to repair genomic damage, or it can
induce apoptosis. Loss of p53 function plays a central role
in the development of cancer. In fact, p53 is mutated in
40–80 % of epithelial ovarian cancers [6, 7]. It is known
that BRCA1 interacts with p53 in the normal tumor sup-
pressor pathway. A higher prevalence of p53 mutations has
been identified in the BRCA related tumors than in spo-
radic ovarian cancer [5].
A metastasis suppressor gene on human chromosome
11p11.2 that encodes a glycoprotein of the transmembrane
four superfamily (TM4SF) is the highly glycosylated pro-
tein KAI1 (CD 82). Although the precise biological func-
tions of TM4SF molecules are not fully elucidated, several
studies have shown involvement in cell growth, adhesion,
and motility. This protein is physiologically expressed in a
variety of tissues and was reported to be downregulated in
several types of human cancer, including cancer of the
ovary, cervix, prostate, lung, breast, bladder, colon, and
pancreas [8–10].
Nm23 gene product has activity of nucleoside diphos-
phate kinase (NDPK). Gene has been reported to be
involved in cell proliferation and differentiation. Reduced
expression of the Nm23 gene is implicated in the metastatic
progression of various cancers: breast, ovary, cervix, liver,
colon, gastric, and melanoma. Although expression of
Nm23 is divergent in various malignant tumors, its
downregulated expression seems to be related with
increased metastatic potential in most carcinoma types
[11–13].
The aim of this study was to investigate the expression
of BRCA1 protein as well as p53, Nm23, and KAI1 pro-
teins associated with tumor metastatic progression in
ovarian tissue removed during prophylactic adnexectomy
in BRCA1 mutation carriers.
Materials and methods
Ovarian tissue was collected from BRCA1 mutation posi-
tive patients during prophylactic bilateral adnexectomy. As
a control group, samples from patients operated in our
Department from other than cancer reason were evaluated.
All patients in control group were not BRCA mutation
carriers.
Immunohistochemical staining for analyzed proteins
was performed on frozen 5-lm tissue sections using the
Universal DakoCytomation LSAB ? Kit, Peroxidase pro-
cedure (LSAB ? Kit: HRP, Dako, Copenhagen, Denmark)
and following primary antibodies: monoclonal antibody
anti-p53 protein (clone DO-7) (Novocastra, Newcastle,
UK), monoclonal antibody anti-nm23 protein (Novocas-
tra), monoclonal antibody anti-KAI 1 (G-2) (Santa Cruz,
USA), and polyclonal antibody anti-BRCA1 (C-20) protein
(Santa Cruz). Nonspecific tissue and endogenous peroxi-
dase reactivity were blocked with 10 % BSA (Bovine
serum albumin) and 3 % H2O2, respectively. Tissue spec-
imens were incubated with primary antibodies 60 min at
room temperature. Following washing with 0.1 M Tris-
buffer, pH 7.4 (TBS), the tissue specimens were incubated
with secondary biotinylated rabbit antibody, anti-mouse/
rabbit IgG (Dako, Denmark) and with streptavidin horse-
radish peroxidase conjugated (Dako) both for 15 min at
room temperature. After washing with TBS, the antigen–
antibody reaction was visualized by DAB (3,3 diam-
inobenzidine) (Dako, Denmark) as a chromogen (8 min,
room temperature). Sections were counterstained with
hematoxylin and mounted. The incubation buffer (TBS)
without primary antibodies was used as negative control.
The internal positive controls were used.
The evaluation of immunohistochemical data was per-
formed as following. Sections were scored semiquantita-
tively, taking into account the intensity of immunostaining
and the number of tumor cells showing the reaction for
p53, Nm23, KAI1, and BRCA1 protein. The cases were
score as positive for p53 protein expression when, more
than 15 % of the tumor cells revealed nuclear immunop-
ositivity. KAI1, Nm23, and BRCA1 expression was
assessed positive if more than 10 % of tissue section
showed immunostaining.
Statistical analysis has been performed using STATIS-
TICA 6.0.
Results
Overall, ovarian tissues from 29 patients were examined.
Studied group included 18 (62 %) patients with BRCA1
mutation (mean age 50.1 ± 8.2). Among those, 10 women
had previous history of breast cancer. Control group
included 11 (38 %) patients operated from other than
cancer reasons (mean age 51.6 ± 10.2). We did not
observe any postoperative complications.
In one woman from a study group, high-grade serous
ovarian cancer was diagnosed. This patient has not suffered
from a breast cancer in the past. After completing staging
surgery, tumor was classified as FIGO IC.
As shown in Fig. 1 expression of BRCA1 protein in
ovarian tissue was presented in 83.3 % (15 pat.) BRCA1
mutation carriers and in 72.7 % (8 pat.) patients in control
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group. Positive expression of p53 protein was observed,
respectively, in 27.8 % (5 pat.) vs. 36.4 % (4 pat.), of
Nm23 protein 77.7 % (14 pat.) vs. 90.9 % (10 pat.), and of
KAI1 in 72.2 % (13 pat.) vs. 72.7 % (8 pat.) cases. Mean
percentage values of tumor cells showing the reaction for
BRCA1, p53, Nm23, and KAI1 proteins are presented in
Fig. 2. It has been identified that mean cell percentage in
which expression of BRCA1 protein was identified in
BRCA1 mutation carriers which reached 33.3 % (6 pat.)
and in the control group 45.4 % (5 pat.), respectively. p53
protein was detected in 5.6 % (1 pat.) vs. 18.1 % (2 pat.),
Nm23 protein 22.2 % (4 pat.) vs. 27.3 % (3 pat.), and
KAI1 33.3 % (6 pat.) vs. 45.4 % (5 pat.) of cells, respec-
tively. Mean values of the intensity of immunostaining for
all analyzed proteins are presented in Fig. 3. For BRCA1
protein, mean value of intensity of immunostaining in
BRCA1 mutation positive group was 1.26 ou/lm2 and in
the control group 1.36 ou/lm2. Accordingly, for p53 pro-
tein 0.47 vs. 0.88 ou/lm2, for Nm23 protein 0.73 vs. 1.20
ou/lm2, and for KAI1 1.24 vs. 1.47 ou/lm2.
The group of BRCA1 mutation carriers has been addi-
tionally evaluated according to medical history of breast
cancer. Positive expression of BRCA1 protein was present
in nine patients (90.0 %) in the group with breast cancer
and in six patients (75.0 %) in BRCA1 mutation carriers
without breast cancer. Positive expression of p53 protein
was observed, respectively, in 4 cases (40.0 %) vs. 1 case
(12.5 %), of Nm23 protein 8 (80. %) vs. 6 (75.0 %), and of
KAI1 in 7 (70. %) vs. 6 (75.0 %). Mean percentage values
of cells showing the reaction for BRCA1 were 30.0 % in
breast cancer group vs. 37.5 % in BRCA1 mutation carriers
without breast cancer. Mean percentage values of the tumor
cells showing the reaction for p53 protein were, respec-
tively, 0 vs. 12,5 %, for Nm23 20.0 vs. 25.0 %, and for
KAI1 30.0 vs. 37.5 %. Mean values of the intensity of
immunostaining for BRCA1 protein were 1.0 ou/lm2 in the
group with breast cancer versus 1.3 ou/lm2 in BRCA1
mutation carriers only without breast cancer. Mean values
of the intensity of immunostaining for p53 protein were,
respectively, 0.41 vs. 0.53 ou/lm2, for Nm23 0.72 vs. 0.75
ou/lm2, and for KAI1 1.1 vs. 1.4 ou/lm2.
Three types of BRCA1 mutations were identified within
the patients in our study. We have not found differences in
patients showing expression of BRCA1, p53, KAI1, and
Nm23 proteins regarding the type of mutation and breast
cancer history (Table 1). According to percent of cells
showing expression of studied genes, we have observed
lower values in patients with breast cancer history in all
types of BRCA1 mutations (Table 2). In Table 3 are pre-
sented mean values of the intensity of immunostaining that
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Fig. 1 The percent of positive expression of BRCA1, p53, Nm23,
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Fig. 2 Mean percentage value of the tumor cells showing the
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Fig. 3 Mean values of the intensity of immunostaining (ou/lm2) for
BRCA 1, p53, Nm23, and KAI1 proteins
Arch Gynecol Obstet (2013) 288:839–844 841
123
Discussion
Recent progress in our understanding of familiar ovarian
cancer has led to significant changes in the day-to-day
practice of surgical pathology [5]. Three cohort studies
have identified a risk reduction with prophylactic bilateral
adnexectomy in women with germ line BRCA1 or 2
mutations by comparing the incidence of ovarian cancer in
the control group to the incidence of primary peritoneal
carcinoma in the prophylactic adnexectomy group.
Assumed analysis showed significant lifetime risk reduc-
tion for developing ovarian cancer and a low probability of
peritoneal cancer in those undergoing surgery [2]. The
development of cancer in BRCA germline mutation carri-
ers occurs only if there is subsequent inactivation of the
remaining wild-type BRCA allele on the opposite chro-
mosome in addition to the pre-existing BRCA germline
mutation [5].
In the study of Wang et al. [14], decreased expression of
BRCA1 was found in 16 % of benign tumors, 38 % of
borderline tumors, and 72 % of carcinomas. These results
suggest that downregulation of BRCA1 protein play an
important role in the development ovarian cancers [14]. In
our study, positive expression of BRCA1 protein was
observed 83.3 % of BRCA1 mutation carriers in compar-
ison to 72.7 % in control group; however, the mean per-
centage value of the tumor cells showing the reaction for
BRCA1 protein in BRCA1 mutation carriers was reduced
in comparison to control group. The same results were
observed in the intensity of immunostaining. Patients with
history of breast cancer have higher expression rate of
BRCA1; however, regarding to mutation of this gene
function its product is impaired.
Loss of p53 function plays a central role in the devel-
opment of cancer. The biological consequence of a mis-
sense mutation is enhancement of p53 stability and
accumulation in the tumor cell nucleus [7]. The p53
alterations indisputably occur more often in BRCA1-
associated tumors than in sporadic breast or ovarian
tumors. This implies that loss of p53 function is a critical
event in the molecular pathogenesis of BRCA1-associated
tumors [15]. In ovarian cancer, immunohistochemical
detectable overexpression of p53 is highly associated with
presence of mutated, nonfunctional p53 [16]. However,
Canevari et al. [7] suggest that p53 mutation is a late event
in ovary carcinogenesis. In our study, the expression, mean
Table 1 BRCA1 mutations
carriers showing expression of
BRCA1, p53, KAI1, and Nm23
proteins
BC breast cancer history,
n number of patients
BRCA1 mutation type BRCA1 p53 KAI1 Nm23
ex 20 (5382 ins C)
All (n = 9) 8 (88.9 %) 3 (33.3 %) 6 (66.7 %) 7 (77.8 %)
BC (n = 6) 6 (100 %) 2 (33.3 %) 4 (66.7 %) 4 (66.7 %)
ex 5 (300 T/G)
All (n = 7) 5 (71.4 %) 1 (14.3 %) 5 (71.4 %) 5 (71.4 %)
BC (n = 3) 2 (66.7 %) 0 (0 %) 3 (100 %) 3 (100 %)
ex 11.17 (4153 del A)
All (n = 2) 2 (100 %) 1 (50 %) 2 (100 %) 2 (100 %)
BC (n = 1) 1 (100 %) 1 (100 %) 1 (100 %) 1 (100 %)
Table 2 Mean percentage value of cells showing the reaction for
BRCA1, p53, KAI1, and Nm23 in BRCA1 mutation carriers indi-











ex 20 (5382 ins C)
No BC (n = 3) 38.3 8.9 40.8 25.1
BC (n = 6) 47 6.7 38.3 21.8
ex 5 (300 T/G)
No BC (n = 4) 36.3 7.5 46.7 7.5
BC (n = 3) 33.3 3.3 18.8 31.7
ex 11.17 (4153 del A)
No BC (n = 1) 30 11.4 47.5 32.5
BC (n = 1) 20 15 15 25
BC breast cancer history, n number of patients
Table 3 Mean values of the intensity of immunostaining (ou/lm2)
for BRCA1, p53, KAI1, and Nm23 in BRCA1 mutation carriers
indicating the type of BRCA1 mutation and the breast cancer history
BRCA1 mutation type BRCA1 p53 KAI1 Nm23
ex 20 (5382 ins C)
No BC (n = 3) 0.67 0.58 1.5 1
BC (n = 6) 1.38 0.42 1.21 0.63
ex 5 (300 T/G)
No BC (n = 4) 1.31 0.31 0.75 0.56
BC (n = 3) 1 0.33 1.58 0.75
ex 11.17 (4153 del A)
No BC (n = 1) 1.75 1 1.75 0.75
BC (n = 1) 2.5 1 1.75 1.25
BC breast cancer history, n number of patients
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percentage value of tumor cells presenting expression as
well as intensity of immunostaining of p53 in BRCA1
mutation carriers were reduced in comparison to the con-
trol group. Lowest values have been noted in the study
group patients with a history of breast cancer.
KAI1 is well known as a prostate cancer gene [9]. A
report by Liu et al. [17] suggested that the downregulation
of KAI1 expression may have a negative impact on sur-
vival in ovarian cancer. Also results by Houle et al. [9]
suggest that the malignant progression of epithelial ovarian
carcinomas is associated with downregulation and altered
cellular localization of KAI1. Liu et al. [17] were unable to
find any mutation of the KAI1 gene in primary or recurrent
ovarian carcinomas except a missense polymorphism in
codon 241. This finding confirms the observation that
downregulation, rather than mutation, is a more common
mechanism for the dysregulation of the KAI1 gene [17]. In
human prostatic cancer, the expression of KAI1 was
reported to be strongly correlated with that of p53, and the
loss of both proteins was associated with poor survival
[18]. This correlation was not found in ovarian carcinoma
[8]. Houle et al. [9] observed a shift in protein localization
of KAI1 from the membrane in grade 1 tumors to the
cytoplasm in grade 3 tumors. They suggest that these
changing patterns of expression from the membrane may
be a mechanism by which tumor cells lose their adhesive
properties during malignant transformation. In our study,
expression of KAI1 in samples from BRCA1 mutation
carriers seems to be downregulated again with lowest
values in patients with a history of previous breast cancer.
Also in our study, no correlation between KAI1 and p53
was found.
As the Nm23/NDP kinase-A gene was discovered in a
murine melanoma metastasis model system, the correlation
of its expression with tumor metastatic potential in actual
human cancers was a subject of great interest [19]. How-
ever, breast carcinoma and melanoma are the two tumor
types most studied in this context [19]; there are also
reports in ovarian carcinoma [12, 20]. In study by Gao
et al. [20], the expression of Nm23 RNA in human ovarian
cancer cells was inversely related to metastatic behavior in
the experimental animals and strongly suggested that the
Nm23 expression correlates with reduced metastasis of
ovarian carcinoma. Elevated Nm23 expression is also
related to lower rates of lymph node metastasis and longer
survival in endometrial cancer. Lower expression of Nm23
is an indicator of poor prognosis and may increase the risk
of regional lymph node metastasis [21]. Adverse results
reported by Srivatsa et al. [12] showed that expression of
Nm23 is strongly upregulated in most epithelial ovarian
cancer and suggest that Nm23 gene expression may have
distinct if not opposite biologic functions in epithelial
ovarian cancer and breast carcinoma.
Conclusions
Observed lower expression of BRCA1, KAI1, NM23, and
p53 may suggest the role of these proteins in carcinogen-
esis and poorer prognosis of hereditary ovarian cancer.
However, no significant statistical differences between
relatively small studied groups were found, the trends
suggesting downregulation of these proteins in BRCA1
mutation carriers was reported. Lowest values were
observed in patients with previous history of breast cancer
of study group what might suggest that downregulation of
studied proteins is combined with higher risk of
carcinogenesis.
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